Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit

International Journal of Pharmaceutics

Volumn 478, Issue 1, 2015, Pages 180-186

  Leonardi, Antonio ^a   Bucolo, Claudio ^a   Drago, Filippo ^a   Salomone, Salvatore ^a   Pignatello, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Eye drops; Glaucoma; Intraocular pressure; Melatonin; Nanoparticles

Indexed keywords

CATIONIC SOLID LIPID NANOPARTICLE; MELATONIN; NANOCARRIER; PALMITIC ACID; SOLID LIPID NANOPARTICLE; STEARIC ACID; UNCLASSIFIED DRUG; LIPID; NANOPARTICLE; SOFTISAN 100; STEARIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; ELECTROPHORETIC MOBILITY; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MALE; NANOENCAPSULATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SURFACE CHARGE; SURFACE PROPERTY; TONOMETER; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; RABBIT;

ANIMALS; DRUG LIBERATION; INTRAOCULAR PRESSURE; LIPIDS; MALE; MELATONIN; NANOPARTICLES; PALMITIC ACID; RABBITS; STEARIC ACIDS;

EID: 84911874105     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.11.032     Document Type: Article

References (43)

1. A. Agorastos, and C.G. Huber The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential J. Pineal. Res. 50 2011 1 7
2. P. Alarma-Estrany, and J. Pintor Melatonin receptors in the eye: location, second messengers and role in ocular physiology Pharmacol. Ther. 113 2007 507 522
3. S. Alcantara-Contreras, K. Baba, and G. Tosini Removal of MEL receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse Neurosci. Lett. 494 2011 61 64
4. V. Andrés-Guerrero, I.T. Molina-Martínez, and A. Peral The use of mucoadhesive polymers to enhance the hypotensive effect of a MEL analogue, 5-MCA-NAT, in rabbit eyes Invest. Ophthalmol. Vis. Sci. 52 2011 1507 1515
5. E. Başaran, M. Demirel, B. Sirmagül, and Y. Yazan Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery J. Microencapsulation 27 2010 37 47
6. M. Basha, S.H. Abdel-Alim, R.N. Shamma, and G.E. Awad Design and optimization of surfactant-based nanovesicles for ocular delivery of clotrimazole J. Liposome Res. 23 2013 203 210
7. C. Bucolo, F. Drago, and S. Salomone Ocular drug delivery: a clue from nanotechnology Front. Pharmacol. 3 2012 188
8. C. Bucolo, S. Salomone, and F. Drago Pharmacological management of ocular hypertension: current approaches and future prospective Curr. Opin. Pharmacol. 13 2013 50 55
9. C. Carbone, A. Leonardi, and S. Cupri Pharmaceutical and biomedical applications of lipid-based nanocarriers Pharm. Pat. Analyst 3 2014 199 215
10. A.M. De Campos, A. Sanchez, R. Gref, P. Calvo, and M.J. Alonso The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa Eur. J. Pharm. Sci. 20 2003 73 81
11. M.L. Dubocovich Melatonin is a potent modulator of dopamine release in the retina Nature 306 1983 782 784
12. J.F. Fangueiro, E. Gonzalez-mira, and P. Martins-lopes A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing Pharm. Dev. Technol. 18 2013 545 549
13. J.F. Fangueiro, T. Andreani, and M.A. Egea Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity Int. J. Pharm. 461 2014 64 73
14. C. Giannavola, C. Bucolo, and A. Maltese Influence of preparation conditions on acyclovir-loaded poly-,-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability Pharm. Res. 20 2003 584 590
15. E. Gonzalez-Mira, M.A. Egea, M.L. Garcia, and E.B. Souto Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC Colloids Surf. B Biointerfaces 81 2010 412 421
16. E. Gonzalez-Mira, S. Nikolić, and M.L. García Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen J. Pharm. Sci. 100 2011 242 251
17. K. Hippalgaonkar, G.R. Adelli, and K. Hippalgaonkar Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation J. Ocul. Pharmacol. Ther. 29 2013 216 228
18. T. Ido, G. Tomita, and Y. Kitazawa Diurnal variation of intraocular pressure of normal-tension glaucoma: influence of sleep and arousal Ophthalmology 98 1991 296 300
19. R. Jockers, P. Maurice, J.A. Boutin, and P. Delagrange Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br. J. Pharmacol. 154 2008 1182 1195
20. M.A. Kalam, Y. Sultana, and A. Ali Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system J. Drug Target. 18 2010 191 204
21. A. Leonardi, C. Bucolo, and G.L. Romano Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles Int. J. Pharm. 470 2014 133 140
22. A. Leonardi, L. Crascì, A. Panico, and R. Pignatello Antioxidant activity of idebenone-loaded neutral and cationic solid lipid nanoparticles Pharm. Dev. Technol. 2014 10.3109/10837450.2014.915572
23. M.A. Liebert Final report on the safety assessment of oleic acid, lauric acid, palmitic acid, myristic acid, and stearic acid Int. J. Toxicol. 6 1987 321 401
24. A. Ludwig The use of mucoadhesive polymers in ocular drug delivery Adv. Drug. Deliv. Rev. 57 2005 1595 1639
25. P.O. Lundmark, S.R. Pandi-perumal, and V. Srinivasan Melatonin in the eye: implications for glaucoma Exp. Eye Res. 84 2007 1021 1030
26. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
27. A. Manosroi, K. Thathang, and R.G. Werner Development of highly stable and lo toxic cationic liposomes for gene therapy Arzneimittelforschung 58 2008 485 492
28. T. Martins De Lima, M.F. Cury-Boaventura, and G. Giannocco Comparative toxicity of fatty acids on a macrophage cell line (J774) Clin. Sci. 111 2006 307 317
29. A. Masotti, G. Mossa, and C. Cametti Comparison of different commercially available cationic liposome-DNA lipoplexes: parameters influencing toxicity and transfection efficiency Colloids Surf. B Biointerfaces 68 2009 136 144
30. T. Musumeci, C. Bucolo, and C. Carbone Polymeric nanoparticles augment the ocular hypotensive effect of MEL in rabbits Int. J. Pharm. 440 2013 135 140
31. R.C. Nagarwal, S. Kant, P.N. Singh, P. Maiti, and J.K. Pandit Polymeric nanoparticulate system: a potential approach for ocular drug delivery J. Control Release 136 2009 2 13
32. B. Nemesure, R. Honkanen, and A. Hennis The Barbados Eye Studies Group. Incident open-angle glaucoma and intraocular pressure Ophthalmology 114 2007 1810 1815
33. R. Pignatello, and G. Puglisi Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity Recent Pat. Nanomed. 1 2011 42 52
34. R. Pignatello, C. Bucolo, and P. Ferrara Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen Eur. J. Pharm. Sci. 16 2002 53 61
35. R. Pignatello, C. Bucolo, and G. Spedalieri Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application Biomaterials 23 2002 3247 3255
36. R. Pignatello, N. Ricupero, and C. Bucolo Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene AAPS PharmSciTech 7 2006 E27
37. L. Priano, D. Esposti, and R. Esposti Solid lipid nanoparticles incorporating MEL as new model for sustained oral and transdermal delivery systems J. Nanosci. Nanotechnol. 7 2007 3596 3601
38. L. Rabinovich-Guilatt, P. Couvreur, G. Lambert, and C. Dubernet Cationic vectors in ocular drug delivery J. Drug. Target. 12 2004 623 633
39. R. Rezzani, L.F. Rodella, and F. Fraschini MEL delivery in solid lipid nanoparticles: prevention of cyclosporine A induced cardiac damage J. Pineal Res. 46 2009 255 261
40. J.B. Serle, R.F. Wang, W.M. Peterson, R. Plourde, and B.R. Yerxa Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intra- ocular pressure in glaucomatous monkey eyes J. Glaucoma 13 2004 385 388
41. A.H.S. Stancampiano, R. Acquaviva, and A. Campisi Technological and biological characterization of idebenone-loaded Solid Lipid Nanoparticles prepared by a modified solvent injection technique J. Biomed. Nanotechnol. 2 2006 253 260
42. R. Tursilli, A. Casolari, V. Iannuccelli, and S. Scalia Enhancement of MEL photostability by encapsulation in lipospheres J. Pharm. Biomed. Anal. 40 2006 910 914
43. A.F. Wiechmann, and J.A. Summers Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues Prog. Retin. Eye Res. 27 2008 137 160